Marshall Wace, LLP Immuneering Corp Transaction History
Marshall Wace, LLP
- $74.4 Billion
- Q1 2025
A detailed history of Marshall Wace, LLP transactions in Immuneering Corp stock. As of the latest transaction made, Marshall Wace, LLP holds 807,969 shares of IMRX stock, worth $1.22 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
807,969
Previous 21,432
3669.92%
Holding current value
$1.22 Million
Previous $47,000
2512.77%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding IMRX
# of Institutions
37Shares Held
4.78MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.06MShares$1.6 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD659KShares$995,1030.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$805,3790.0% of portfolio
-
Morgan Stanley New York, NY467KShares$705,5110.0% of portfolio
-
Southport Management, L.L.C. Wilson, WY245KShares$369,9501.61% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $39.9M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...